A carregar...
US Budget Impact Model for Selinexor in Relapsed or Refractory Multiple Myeloma
OBJECTIVE: To estimate the budgetary impact of adopting selinexor (XPOVIO; Karyopharm Therapeutics, Inc.) for the treatment of adult patients with penta-refractory multiple myeloma (MM) from the perspective of a third-party payer in the United States (US). METHODS: A budget impact analysis was condu...
Na minha lista:
| Publicado no: | Clinicoecon Outcomes Res |
|---|---|
| Main Authors: | , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Dove
2020
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7310980/ https://ncbi.nlm.nih.gov/pubmed/32606848 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/CEOR.S251070 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|